Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 14Carcinoma, Non-Small-Cell Lung 13Neoplasms 10Glioblastoma 9Fallopian Tube Neoplasms 8Colorectal Neoplasms 8Breast Neoplasms 8Lung Neoplasms 7Rectal Neoplasms 6Neoplasm Metastasis 6Gliosarcoma 6Colonic Neoplasms 6Carcinoma, Renal Cell 6Brain Neoplasms 6Prostatic Neoplasms 4Melanoma 4Uterine Cervical Neoplasms 3Solitary Fibrous Tumor, Pleural 3Sarcoma, Alveolar Soft Part 3Sarcoma 3Mesothelioma, Malignant 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Advanced Solid Tumor 3Uveal Melanoma 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1pembrolizumab 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1atezolizumab 1ZD4054 1Topotecan 1Tiragolumab 1Rosuvastatin Calcium 1Radiotherapy 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Malignancies × cediranib × Clear all
NCT00981721 2011-06-20

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
20 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡